ARTICLE | Company News
Alopexx Pharmaceuticals, sanofi-aventis deal
December 14, 2009 8:00 AM UTC
Alopexx granted sanofi-aventis an option to license exclusive, worldwide rights to F598. The mAb against poly-N-acetyl glucosamine (PNAG) is expected to begin Phase I testing next year to treat and ...